{"product_id":"holland-frei-cancer-medicine-isbn-9781119750680","title":"Holland-Frei Cancer Medicine","description":"\u003cb\u003eHOLLAND-FREI CANCER MEDICINE\u003c\/b\u003e \u003cp\u003e\u003cb\u003eThe latest edition of the gold-standard in cancer science and clinical oncology references\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIn the newly revised Tenth Edition of \u003ci\u003eHolland-Frei Cancer Medicine\u003c\/i\u003e, a team of distinguished researchers and practitioners delivers a comprehensive and up-to-date discussion of cancer science and clinical oncology practice. The book contains timely and indispensable information on epidemiology, etiology, cancer biology, immunology, prevention, screening, clinical presentation, pathology, imaging, and therapy.\u003c\/p\u003e \u003cp\u003eGrounded in a fundamental understanding of cancer biology, \u003ci\u003eHolland-Frei Cancer Medicine\u003c\/i\u003e combines scientific principles with clinical practice. It contains hundreds of full-color illustrations and photographs, tables, graphs, and algorithms that complement and enhance the complex topics discussed within the book. This book is an invaluable clinical tool that provides readers with overview boxes, additional references, and other pedagogic features designed to make the content easy to access and comprehend.\u003c\/p\u003e \u003cp\u003eReaders will also find:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eA translational and integrated approach throughout the book that combines cancer biology with cancer management\u003c\/li\u003e \u003cli\u003eA strong emphasis on multidisciplinary, research-driven patient care that improves outcomes and allows for the optimal use of all clinically appropriate therapies\u003c\/li\u003e \u003cli\u003eDiscussions of the most current personalized cancer care, including molecular diagnostics and therapeutics\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003ePerfect for medical oncologists, radiation oncologists, and internists, \u003ci\u003eHolland-Frei Cancer Medicine, Tenth Edition \u003c\/i\u003ewill also earn a place in the libraries of allied health professionals involved in the treatment of cancer patients.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e \u003cp\u003eThis book is published in collaboration with the American Association for Cancer Research: \u003ca href=\"https:\/\/www.aacr.org\/\"\u003ehttps:\/\/www.aacr.org\/\u003c\/a\u003e\u003c\/p\u003eDie neueste Ausgabe des Goldstandards in der Krebsforschung und klinischen Onkologie\u003cbr\u003e \u003cbr\u003e Mit der neu überarbeiteten zehnten Ausgabe von Holland-Frei Cancer Medicine legt ein Team anerkannter Forscher und Ärzte einen umfassenden aktuellen Überblick über die Krebsforschung und die klinische onkologische Praxis vor. Das Werk enthält zeitgemäße und unverzichtbare Informationen aus den Bereichen Epidemiologie, Ätiologie, Krebsbiologie, Immunologie, Prävention, Screening, klinisches Erscheinungsbild, Pathologie, Bildgebung und Therapie.\u003cbr\u003e \u003cbr\u003e Ausgehend von einem grundlegenden Verständnis der Krebsbiologie stellt Holland-Frei Cancer Medicine eine Verbindung zwischen wissenschaftlichen Prinzipien und klinischer Praxis her. Das Buch enthält Hunderte farbiger Abbildungen und Fotos, Tabellen, Grafiken und Algorithmen, um die im Text erörterten komplexen Inhalte zu ergänzen und zu vertiefen. Das unverzichtbare klinische Lehrbuch ist darauf ausgelegt, die Inhalte mit separaten Zusammenfassungen, zusätzlichen Verweisen und anderen pädagogischen Merkmalen übersichtlich und leicht verständlich zu präsentieren.\u003cbr\u003e \u003cbr\u003e Außerdem bietet das Werk:\u003cbr\u003e * Einen integrierten translationalen Ansatz, der die Krebsbiologie mit dem Krebsmanagement verbindet\u003cbr\u003e * Einen starken Fokus auf die multidisziplinäre, forschungsorientierte Patientenversorgung, wodurch bessere Ergebnisse erzielt und der optimale Einsatz aller klinisch geeigneten Therapien ermöglicht werden sollen\u003cbr\u003e * Eine Erörterung des neuesten Trends der personalisierten Krebsbehandlung mit molekularer Diagnostik und Therapeutik\u003cbr\u003e \u003cbr\u003e Die zehnte Auflage von Holland-Frei Cancer Medicine richtet sich nicht nur an medizinische Onkologen, Strahlenonkologen und Internisten, sondern hat auch einen Platz in den Bibliotheken anderer Gesundheitsfachkräfte verdient, die sich mit der Behandlung von Krebspatienten beschäftigen.\u003cbr\u003e \u003cbr\u003e Dieses Werk wird in Zusammenarbeit mit der American Association for Cancer Research herausgegeben: https:\/\/www.aacr.org\/ \u003cp\u003eList of contributors xi\u003c\/p\u003e \u003cp\u003ePreface xxvii\u003c\/p\u003e \u003cp\u003eAcknowledgments xxix\u003c\/p\u003e \u003cp\u003ePart 1: INTRODUCTION\u003c\/p\u003e \u003cp\u003e1 Cardinal manifestations of cancer 3\u003c\/p\u003e \u003cp\u003eJames F. Holland, Robert C. Bast, Jr., John C. Byrd,\u003c\/p\u003e \u003cp\u003eCarlo M. Croce, Ernest Hawk, Fadlo R. Khuri, Raphael\u003c\/p\u003e \u003cp\u003eE. Pollock, Apostolia M. Tsimberadou, Christopher G.\u003c\/p\u003e \u003cp\u003eWillett, and Cheryl L.Willman\u003c\/p\u003e \u003cp\u003e2 Biological hallmarks of cancer 7\u003c\/p\u003e \u003cp\u003eDouglas Hanahan and Robert A.Weinberg\u003c\/p\u003e \u003cp\u003ePart 2: TUMOR BIOLOGY\u003c\/p\u003e \u003cp\u003e3 Molecular biology, genetics, and translational\u003c\/p\u003e \u003cp\u003emodels of human cancer 19\u003c\/p\u003e \u003cp\u003eBenno Traub, Florian Scheufele, Srinivas R.\u003c\/p\u003e \u003cp\u003eViswanathan, Matthew Meyerson, and David A. Tuveson\u003c\/p\u003e \u003cp\u003e4 Oncogenes 49\u003c\/p\u003e \u003cp\u003eMarco A. Pierotti, Milo Frattini, Samantha Epistolio,\u003c\/p\u003e \u003cp\u003eGabriella Sozzi, and Carlo M. Croce\u003c\/p\u003e \u003cp\u003e5 Tumor suppressor genes 73\u003c\/p\u003e \u003cp\u003eFred Bunz and Bert Vogelstein\u003c\/p\u003e \u003cp\u003e6 Epigenetic contributions to human cancer 89\u003c\/p\u003e \u003cp\u003eStephen B. Baylin\u003c\/p\u003e \u003cp\u003e7 Cancer genomics and evolution 101\u003c\/p\u003e \u003cp\u003eWilliam P. D. Hendricks, Aleksandar Sekulic, Alan H.\u003c\/p\u003e \u003cp\u003eBryce, Muhammed Murtaza, Pilar Ramos, Jessica D.\u003c\/p\u003e \u003cp\u003eLang, Timothy G. Whitsett, Timothy K. McDaniel,\u003c\/p\u003e \u003cp\u003eRussell C. Rockne, Nicholas Banovich, and Jeffrey M. Trent\u003c\/p\u003e \u003cp\u003e8 Chromosomal aberrations in cancer 125\u003c\/p\u003e \u003cp\u003eMegan E. McNerney, Ari J. Rosenberg, and Michelle M.\u003c\/p\u003e \u003cp\u003eLe Beau\u003c\/p\u003e \u003cp\u003e9 MicroRNA expression in cancer 143\u003c\/p\u003e \u003cp\u003eSerge P. Nana-Sinkam, Mario Acunzo, and Carlo M. Croce\u003c\/p\u003e \u003cp\u003e10 Aberrant signaling pathways in cancer 151\u003c\/p\u003e \u003cp\u003eLuca Grumolato and Stuart A. Aaronson\u003c\/p\u003e \u003cp\u003e11 Differentiation therapy 161\u003c\/p\u003e \u003cp\u003eSai-Juan Chen, Xiao-Jing Yan, Guang-Biao Zhou, and\u003c\/p\u003e \u003cp\u003eZhu Chen\u003c\/p\u003e \u003cp\u003e12 Cancer stem cells 177\u003c\/p\u003e \u003cp\u003eGrace G. Bushnell,Michael D. Brooks, andMax S.Wicha\u003c\/p\u003e \u003cp\u003e13 Cancer and cell death 187\u003c\/p\u003e \u003cp\u003eJohn C. Reed\u003c\/p\u003e \u003cp\u003e14 Cancer cell immortality: targeting telomerase and\u003c\/p\u003e \u003cp\u003etelomeres 201\u003c\/p\u003e \u003cp\u003eIlgen Mender, Zeliha G. Dikmen, and JerryW. Shay\u003c\/p\u003e \u003cp\u003e15 Cancer metabolism 211\u003c\/p\u003e \u003cp\u003eNatalya N. Pavlova, Aparna D. Rao, Ralph J.\u003c\/p\u003e \u003cp\u003eDeBerardinis, and Craig B.Thompson\u003c\/p\u003e \u003cp\u003e16 Tumor angiogenesis 223\u003c\/p\u003e \u003cp\u003eJohn V. Heymach, Amado Zurita-Saavedra, Scott\u003c\/p\u003e \u003cp\u003eKopetz, Tina Cascone, MoniqueNilsson, and IreneGuijarro\u003c\/p\u003e \u003cp\u003ePart 3: QUANTITATIVE ONCOLOGY\u003c\/p\u003e \u003cp\u003e17 Cancer bioinformatics 247\u003c\/p\u003e \u003cp\u003eJohn N.Weinstein\u003c\/p\u003e \u003cp\u003e18 Systems biology and genomics 261\u003c\/p\u003e \u003cp\u003eSaima Hassan, Joe W. Gray, and LauraM.Heiser\u003c\/p\u003e \u003cp\u003e19 Statistical innovations in cancer research 269\u003c\/p\u003e \u003cp\u003eJ. Jack Lee and Donald A. Berry\u003c\/p\u003e \u003cp\u003e20 Biomarker based clinical trial design in the era of\u003c\/p\u003e \u003cp\u003egenomic medicine 285\u003c\/p\u003e \u003cp\u003eR.Donald Harvey, Yuan Liu, Taofeek K.Owonikoko,\u003c\/p\u003e \u003cp\u003eand Suresh S. Ramalingam\u003c\/p\u003e \u003cp\u003e21 Clinical and research informatics data strategy for\u003c\/p\u003e \u003cp\u003eprecision oncology 293\u003c\/p\u003e \u003cp\u003eDouglas Hartman, Uma Chandran, Michael Davis,\u003c\/p\u003e \u003cp\u003eRajiv Dhir,William E. Shirey, Jonathan C. Silverstein,\u003c\/p\u003e \u003cp\u003eand Michael J. Becich\u003c\/p\u003e \u003cp\u003ePart 4: CARCINOGENESIS\u003c\/p\u003e \u003cp\u003e22 Chemical carcinogenesis 305\u003c\/p\u003e \u003cp\u003eLorne J. Hofseth, AinsleyWeston, and Curtis C. Harris\u003c\/p\u003e \u003cp\u003e23 Ionizing radiation 325\u003c\/p\u003e \u003cp\u003eDavid J. Grdina\u003c\/p\u003e \u003cp\u003e24 Ultraviolet radiation carcinogenesis 333\u003c\/p\u003e \u003cp\u003eJames E. Cleaver, Susana Ortiz-Urda, and Sarah Arron\u003c\/p\u003e \u003cp\u003e25 Inflammation and cancer 339\u003c\/p\u003e \u003cp\u003eJelena Todoric, Atsushi Umemura, Koji Taniguchi, and\u003c\/p\u003e \u003cp\u003eMichael Karin\u003c\/p\u003e \u003cp\u003e26 RNA tumor viruses 347\u003c\/p\u003e \u003cp\u003eRobert C. Gallo and Marvin S. Reitz\u003c\/p\u003e \u003cp\u003e27 Herpesviruses 359\u003c\/p\u003e \u003cp\u003eJeffrey I. Cohen\u003c\/p\u003e \u003cp\u003e28 Papillomaviruses and cervical neoplasia 367\u003c\/p\u003e \u003cp\u003eMichael F. Herfs, Christopher P. Crum, and KarlMunger\u003c\/p\u003e \u003cp\u003e29 Hepatitis viruses and hepatoma 373\u003c\/p\u003e \u003cp\u003eHongyangWang\u003c\/p\u003e \u003cp\u003e30 Parasites 379\u003c\/p\u003e \u003cp\u003eMervat El Azzouni, Charbel F. Matar, Radwa Galal,\u003c\/p\u003e \u003cp\u003eElio Jabra, and Ali Shamseddine\u003c\/p\u003e \u003cp\u003ePart 5: EPIDEMIOLOGY, PREVENTION, AND\u003c\/p\u003e \u003cp\u003eDETECTION\u003c\/p\u003e \u003cp\u003e31 Cancer epidemiology 391\u003c\/p\u003e \u003cp\u003eVeronika Fedirko, Kevin T. Nead, Carrie Daniel, and\u003c\/p\u003e \u003cp\u003ePaul Scheet\u003c\/p\u003e \u003cp\u003e32 Hereditary cancer syndromes: risk assessment and\u003c\/p\u003e \u003cp\u003egenetic counseling 403\u003c\/p\u003e \u003cp\u003eRachel Bluebond, Sarah A. Bannon, Samuel M. Hyde,\u003c\/p\u003e \u003cp\u003eAshley H.Woodson, Nancy Y.-Q. You, Karen H. Lu, and\u003c\/p\u003e \u003cp\u003eBanu Arun\u003c\/p\u003e \u003cp\u003e33 Behavioral approaches to cancer prevention 425\u003c\/p\u003e \u003cp\u003eRoberto Gonzalez and Maher Karam-Hage\u003c\/p\u003e \u003cp\u003e34 Diet and nutrition in the etiology and prevention\u003c\/p\u003e \u003cp\u003eof cancer 433\u003c\/p\u003e \u003cp\u003eSteven K. Clinton, Edward L. Giovannucci, Fred K.\u003c\/p\u003e \u003cp\u003eTabung, and Elizabeth M. Grainger\u003c\/p\u003e \u003cp\u003e35 Chemoprevention of cancer 453\u003c\/p\u003e \u003cp\u003eErnest Hawk, Karen C. Maresso, Powel Brown, Michelle\u003c\/p\u003e \u003cp\u003eI. Savage, and Scott M. Lippman\u003c\/p\u003e \u003cp\u003e36 Cancer screening and early detection 473\u003c\/p\u003e \u003cp\u003eOtisW. Brawley\u003c\/p\u003e \u003cp\u003ePart 6: CLINICAL DISCIPLINES\u003c\/p\u003e \u003cp\u003e37 Clinical cancer genomic diagnostics and modern\u003c\/p\u003e \u003cp\u003ediagnostic pathology 493\u003c\/p\u003e \u003cp\u003eKatherine Roth, Stephen B. Gruber, and Kevin McDonnell\u003c\/p\u003e \u003cp\u003e38 Molecular diagnostics in cancer 505\u003c\/p\u003e \u003cp\u003eZachary L. Coyne, Roshni D. Kalachand, Robert C. Bast\u003c\/p\u003e \u003cp\u003eJr., Gordon B. Mills, and Bryan T. Hennessy\u003c\/p\u003e \u003cp\u003e39 Principles of imaging 519\u003c\/p\u003e \u003cp\u003eLawrence H. Schwartz\u003c\/p\u003e \u003cp\u003e40 Interventional radiology for the cancer patient 521\u003c\/p\u003e \u003cp\u003eZeyad A. Metwalli, Judy U. Ahrar, andMichael J. Wallace\u003c\/p\u003e \u003cp\u003e41 Principles of surgical oncology 531\u003c\/p\u003e \u003cp\u003eToddW. Bauer, Kenneth K. Tanabe, and Raphael E. Pollock\u003c\/p\u003e \u003cp\u003e42 Principles of radiation oncology 543\u003c\/p\u003e \u003cp\u003eScott R. Floyd, Justus Adamson, Philip P. Connell, Ralph\u003c\/p\u003e \u003cp\u003eR.Weichselbaum, and Christopher G.Willett\u003c\/p\u003e \u003cp\u003e43 Principles of medical oncology 553\u003c\/p\u003e \u003cp\u003eApostolia M. Tsimberidou, Robert C. Bast, Jr., Fadlo R.\u003c\/p\u003e \u003cp\u003eKhuri, and John C. Byrd\u003c\/p\u003e \u003cp\u003e44 Pain and palliative care 567\u003c\/p\u003e \u003cp\u003eLaura Van Metre Baum and Cardinale B. Smith\u003c\/p\u003e \u003cp\u003e45 Psycho-oncology 577\u003c\/p\u003e \u003cp\u003eDiya Banerjee and Andrew J. Roth\u003c\/p\u003e \u003cp\u003e46 Principles of cancer rehabilitation medicine 585\u003c\/p\u003e \u003cp\u003eMichael D. Stubblefield, Miguel Escalon, Sofia A.\u003c\/p\u003e \u003cp\u003eBarchuk, Krina Vyas, and David C.Thomas\u003c\/p\u003e \u003cp\u003e47 Integrative oncology in cancer care 593\u003c\/p\u003e \u003cp\u003eGabriel Lopez,Wenli Liu, Santhosshi Narayanan, and\u003c\/p\u003e \u003cp\u003eLorenzo Cohen\u003c\/p\u003e \u003cp\u003e48 Health services research 599\u003c\/p\u003e \u003cp\u003eMichaela A. Dinan and Devon K. Check\u003c\/p\u003e \u003cp\u003ePart 7: INDIVIDUALIZED TREATMENT\u003c\/p\u003e \u003cp\u003e49 Precision medicine in oncology drug development 613\u003c\/p\u003e \u003cp\u003eApostolia M. Tsimberidou, Elena Fountzilas, and\u003c\/p\u003e \u003cp\u003eRazelle Kurzrock\u003c\/p\u003e \u003cp\u003ePart 8: CHEMOTHERAPY\u003c\/p\u003e \u003cp\u003e50 Drug development of small molecule cancer\u003c\/p\u003e \u003cp\u003etherapeutics in an Academic Cancer Center 631\u003c\/p\u003e \u003cp\u003eChristopher C. Coss, Jeffrey T. Patrick, Damien Gerald,\u003c\/p\u003e \u003cp\u003eGerard Hilinski, Reena Shakya, and John C. Byrd\u003c\/p\u003e \u003cp\u003e51 Principles of dose, schedule, and combination\u003c\/p\u003e \u003cp\u003etherapy 641\u003c\/p\u003e \u003cp\u003eJoseph P. Eder and Navid Hafez\u003c\/p\u003e \u003cp\u003e52 Pharmacology of small-molecule anticancer agents 655\u003c\/p\u003e \u003cp\u003eZahra Talebi, Sharyn D. Baker, and Alex Sparreboom\u003c\/p\u003e \u003cp\u003e53 Folate antagonists 667\u003c\/p\u003e \u003cp\u003eLisa Gennarini, Peter D. Cole, and Joseph R. Bertino\u003c\/p\u003e \u003cp\u003e54 Pyrimidine and purine antimetabolites 679\u003c\/p\u003e \u003cp\u003eRobert B. Diasio and StevenM. Offer\u003c\/p\u003e \u003cp\u003e55 Alkylating agents and platinum antitumor\u003c\/p\u003e \u003cp\u003ecompounds 693\u003c\/p\u003e \u003cp\u003eZahid H. Siddik\u003c\/p\u003e \u003cp\u003e56 DNA topoisomerase targeting drugs 701\u003c\/p\u003e \u003cp\u003eAnishThomas, Susan Bates,William D. Figg, Sr., and\u003c\/p\u003e \u003cp\u003eYves Pommier\u003c\/p\u003e \u003cp\u003e57 Microtubule inhibitors 717\u003c\/p\u003e \u003cp\u003eGiuseppe Galletti and Paraskevi Giannakakou\u003c\/p\u003e \u003cp\u003e58 Drug resistance and its clinical circumvention 731\u003c\/p\u003e \u003cp\u003eJeffrey A. Moscow, Shannon K. Hughes, Kenneth H.\u003c\/p\u003e \u003cp\u003eCowan, and Branimir I. Sikic\u003c\/p\u003e \u003cp\u003ePart 9: BIOLOGICAL AND GENE THERAPY\u003c\/p\u003e \u003cp\u003e59 Cytokines, interferons, and hematopoietic growth\u003c\/p\u003e \u003cp\u003efactors 739\u003c\/p\u003e \u003cp\u003eNarendranath Epperla,Walter Hanel, and Moshe Talpaz\u003c\/p\u003e \u003cp\u003e60 Monoclonal antibody and targeted toxin therapy 755\u003c\/p\u003e \u003cp\u003eRobert C. Bast, Jr. andMichael R. Zalutsky\u003c\/p\u003e \u003cp\u003e61 Vaccines and immunomodulators 781\u003c\/p\u003e \u003cp\u003eJeffrey Schlom, Sofia R. Gameiro, Claudia Palena, and\u003c\/p\u003e \u003cp\u003eJames L. Gulley\u003c\/p\u003e \u003cp\u003e62 T cell immunotherapy of cancer 789\u003c\/p\u003e \u003cp\u003eM. Lia Palomba, Jae H. Park, and Renier Brentjens\u003c\/p\u003e \u003cp\u003e63 Cancer immunotherapy 799\u003c\/p\u003e \u003cp\u003ePadmanee Sharma, Swetha Anandhan, Bilal A.\u003c\/p\u003e \u003cp\u003eSiddiqui, Sangeeta Goswami, Sumit K. Subudhi, Jianjun\u003c\/p\u003e \u003cp\u003eGao, Karl Peggs, Sergio Quezada, and James P. Allison\u003c\/p\u003e \u003cp\u003e64 Cancer gene therapy 817\u003c\/p\u003e \u003cp\u003eHaruko Tashiro, Lauren Scherer, and Malcolm Brenner\u003c\/p\u003e \u003cp\u003e65 Cancer nanotechnology 825\u003c\/p\u003e \u003cp\u003eXingya Jiang, Yanlan Liu, Danny Liu, Jinjun Shi, and\u003c\/p\u003e \u003cp\u003eRobert Langer\u003c\/p\u003e \u003cp\u003e66 Hematopoietic cell transplantation 833\u003c\/p\u003e \u003cp\u003eQaiser Bashir, Elizabeth J. Shpall, and Richard E. Champlin\u003c\/p\u003e \u003cp\u003ePart 10: SPECIAL POPULATIONS\u003c\/p\u003e \u003cp\u003e67 Principles of pediatric oncology 847\u003c\/p\u003e \u003cp\u003eTheodore P. Nicolaides, Elizabeth Raetz, andWilliam L.\u003c\/p\u003e \u003cp\u003eCarroll\u003c\/p\u003e \u003cp\u003e68 Cancer and pregnancy 867\u003c\/p\u003e \u003cp\u003eJennifer K. Litton\u003c\/p\u003e \u003cp\u003e69 Cancer and aging 877\u003c\/p\u003e \u003cp\u003eAshley E. Rosko, Carolyn J. Presley, Grant R.Williams,\u003c\/p\u003e \u003cp\u003eand Rebecca L. Olin\u003c\/p\u003e \u003cp\u003e70 Disparities in cancer care 885\u003c\/p\u003e \u003cp\u003eOtisW. Brawley\u003c\/p\u003e \u003cp\u003e71 Neoplasms in people living with human\u003c\/p\u003e \u003cp\u003eimmunodeficiency virus 895\u003c\/p\u003e \u003cp\u003eChia-Ching J.Wang and Elizabeth Y. Chiao\u003c\/p\u003e \u003cp\u003e72 Cancer survivorship 911\u003c\/p\u003e \u003cp\u003eLewis Foxhall\u003c\/p\u003e \u003cp\u003ePart 11: DISEASE SITES\u003c\/p\u003e \u003cp\u003e73 Primary neoplasms of the brain in adults 921\u003c\/p\u003e \u003cp\u003eMatthew A. Smith-Cohn and Mark R. Gilbert\u003c\/p\u003e \u003cp\u003e74 Neoplasms of the eye and orbit 933\u003c\/p\u003e \u003cp\u003eErica R. Alvarez, Claudia M. Prospero Ponce, Patricia\u003c\/p\u003e \u003cp\u003eChevez-Barrios, and Dan S. Gombos\u003c\/p\u003e \u003cp\u003e75 Neoplasms of the endocrine glands and pituitary\u003c\/p\u003e \u003cp\u003eneoplasms 943\u003c\/p\u003e \u003cp\u003eRui Feng, Chirag D. Gandhi, Margaret Pain, and\u003c\/p\u003e \u003cp\u003eKalmon D. Post\u003c\/p\u003e \u003cp\u003e76 Neoplasms of the thyroid 949\u003c\/p\u003e \u003cp\u003eMatthew D. Ringel\u003c\/p\u003e \u003cp\u003e77 Malignant tumors of the adrenal gland 961\u003c\/p\u003e \u003cp\u003eJeffrey E. Lee, Mouhammed A. Habra, andMatthew T.\u003c\/p\u003e \u003cp\u003eCampbell\u003c\/p\u003e \u003cp\u003e78 Tumors of the diffuse neuroendocrine and\u003c\/p\u003e \u003cp\u003egastroenteropancreatic system 971\u003c\/p\u003e \u003cp\u003eEvan Vosburgh\u003c\/p\u003e \u003cp\u003e79 Neoplasms of the head and neck 981\u003c\/p\u003e \u003cp\u003eRobert L. Ferris, AdamS. Garden, andNabil F. Saba\u003c\/p\u003e \u003cp\u003e80 Cancer of the lung 1005\u003c\/p\u003e \u003cp\u003eDaniel Morgensztern, Daniel Boffa, Alexander Chen,\u003c\/p\u003e \u003cp\u003eAndrew Dhanasopon, Sarah B. Goldberg, Roy H.\u003c\/p\u003e \u003cp\u003eDecker, Siddhartha Devarakonda, Jane P. Ko, Luisa M.\u003c\/p\u003e \u003cp\u003eSolis Soto, Saiama N.Waqar, Ignacio I.Wistuba, and\u003c\/p\u003e \u003cp\u003eRoy S. Herbst\u003c\/p\u003e \u003cp\u003e81 Malignant pleural mesothelioma 1029\u003c\/p\u003e \u003cp\u003eMichele Carbone, Daniel R. Gomez, Anne S. Tsao,\u003c\/p\u003e \u003cp\u003eHaining Yang, and Harvey I. Pass\u003c\/p\u003e \u003cp\u003e82 Thymomas and thymic tumors 1043\u003c\/p\u003e \u003cp\u003eMayur D. Mody,Gabriel L. Sica, Suresh S. Ramalingam,\u003c\/p\u003e \u003cp\u003eand Dong M. Shin\u003c\/p\u003e \u003cp\u003e83 Tumors of the heart and great vessels 1055\u003c\/p\u003e \u003cp\u003eMoritz C.Wyler von Ballmoos and Michael J. Reardon\u003c\/p\u003e \u003cp\u003e84 Primary germ cell tumors of the thorax 1061\u003c\/p\u003e \u003cp\u003eJohn D. Hainsworth and Frank A. Greco\u003c\/p\u003e \u003cp\u003e85 Neoplasms of the esophagus 1065\u003c\/p\u003e \u003cp\u003eMaxW. Sung and Virginia R. Litle\u003c\/p\u003e \u003cp\u003e86 Carcinoma of the stomach 1083\u003c\/p\u003e \u003cp\u003eCarl Schmidt, Nour Daboul, Carly Likar, and JoshuaWeir\u003c\/p\u003e \u003cp\u003e87 Primary neoplasms of the liver 1095\u003c\/p\u003e \u003cp\u003eHop S. Tran Cao, Junichi Shindoh, and Jean-Nicolas\u003c\/p\u003e \u003cp\u003eVauthey\u003c\/p\u003e \u003cp\u003e88 Gallbladder and bile duct cancer 1109\u003c\/p\u003e \u003cp\u003eMariam F. Eskander, Christopher T. Aquina, and\u003c\/p\u003e \u003cp\u003eTimothy M. Pawlik\u003c\/p\u003e \u003cp\u003e89 Neoplasms of the exocrine pancreas 1123\u003c\/p\u003e \u003cp\u003eRobert A. Wolff, Donghui Li, AnirbanMaitra, Susan\u003c\/p\u003e \u003cp\u003eTsai, Eugene Koay, and Douglas B. Evans\u003c\/p\u003e \u003cp\u003e90 Neoplasms of the appendix and peritoneum 1139\u003c\/p\u003e \u003cp\u003eAnnie Liu, Diana Cardona, and Dan Blazer\u003c\/p\u003e \u003cp\u003e91 Carcinoma of the colon and rectum 1147\u003c\/p\u003e \u003cp\u003eYota Suzuki, Douglas S. Tyler, and Uma R. Phatak\u003c\/p\u003e \u003cp\u003e92 Neoplasms of the anus 1169\u003c\/p\u003e \u003cp\u003eAlexandre A. A. Jácome and Cathy Eng\u003c\/p\u003e \u003cp\u003e93 Renal cell carcinoma 1181\u003c\/p\u003e \u003cp\u003eClaude M. Grigg, Earle F. Burgess, Stephen B. Riggs,\u003c\/p\u003e \u003cp\u003eJason Zhu, and Derek Raghavan\u003c\/p\u003e \u003cp\u003e94 Urothelial cancer 1191\u003c\/p\u003e \u003cp\u003eDerek Raghavan, Richard Cote, Earle F. Burgess, Derek\u003c\/p\u003e \u003cp\u003eMcHaffie, and Peter E. Clark\u003c\/p\u003e \u003cp\u003e95 Neoplasms of the prostate 1201\u003c\/p\u003e \u003cp\u003eAna Aparicio, Patrick Pilie, Devaki S. Surasi, Seungtaek\u003c\/p\u003e \u003cp\u003eChoi, Brian F. Chapin, Christopher J. Logothetis, and\u003c\/p\u003e \u003cp\u003ePaul G. Corn\u003c\/p\u003e \u003cp\u003e96 Tumors of the penis and the urethra 1239\u003c\/p\u003e \u003cp\u003eJad Chahoud, Andrea Necchi, and Philippe E. Spiess\u003c\/p\u003e \u003cp\u003e97 Testis cancer 1245\u003c\/p\u003e \u003cp\u003eMichael Hawking, Gladell Paner, Scott Eggener, and\u003c\/p\u003e \u003cp\u003eWalter M. Stadler\u003c\/p\u003e \u003cp\u003e98 Neoplasms of the vulva and vagina 1261\u003c\/p\u003e \u003cp\u003eMichael Frumovitz and Summer B. Dewdney\u003c\/p\u003e \u003cp\u003e99 Neoplasms of the cervix 1275\u003c\/p\u003e \u003cp\u003eAnuja Jhingran\u003c\/p\u003e \u003cp\u003e100 Endometrial cancer 1299\u003c\/p\u003e \u003cp\u003eShannon N.Westin, Karen Lu, and Jamal Rahaman\u003c\/p\u003e \u003cp\u003e101 Epithelial ovarian, fallopian tube, and peritoneal\u003c\/p\u003e \u003cp\u003ecancer 1311\u003c\/p\u003e \u003cp\u003eJonathan S. Berek, Malte Renz, Michael L. Friedlander,\u003c\/p\u003e \u003cp\u003eand Robert C. Bast, Jr.\u003c\/p\u003e \u003cp\u003e102 Nonepithelial ovarian malignancies 1329\u003c\/p\u003e \u003cp\u003eJonathan S. Berek, Malte Renz, Michael L. Friedlander,\u003c\/p\u003e \u003cp\u003eand Robert C. Bast, Jr.\u003c\/p\u003e \u003cp\u003e103 Molar pregnancy and gestational trophoblastic\u003c\/p\u003e \u003cp\u003eneoplasia 1343\u003c\/p\u003e \u003cp\u003eNeil S. Horowitz, Donald P. Goldstein, and Ross S. Berkowitz\u003c\/p\u003e \u003cp\u003e104 Gynecologic sarcomas 1351\u003c\/p\u003e \u003cp\u003eJamal Rahaman and Carmel J. Cohen\u003c\/p\u003e \u003cp\u003e105 Neoplasms of the breast 1361\u003c\/p\u003e \u003cp\u003eDebu Tripathy, Sukh Makhnoon, Banu Arun, Aysegul\u003c\/p\u003e \u003cp\u003eSahin, Nicole M. Kettner, Senthil Damodaran, Khandan\u003c\/p\u003e \u003cp\u003eKeyomarsi,Wei Yang, Kelly K. Hunt, Mark Clemens,\u003c\/p\u003e \u003cp\u003eWendy A. Woodward, Melissa P.Mitchell, Rachel\u003c\/p\u003e \u003cp\u003eLayman, Evthokia A. Hobbs, Bora Lim, MeganDupuis,\u003c\/p\u003e \u003cp\u003eRashmi Murthy, Omar Alhalabi, Nuhad Ibrahim,\u003c\/p\u003e \u003cp\u003eIshwaria M. Subbiah, and Carlos Barcenas\u003c\/p\u003e \u003cp\u003e106 Malignant melanoma 1413\u003c\/p\u003e \u003cp\u003eMichael J. Carr, JustinM. Ko, SusanM. Swetter, Scott E.\u003c\/p\u003e \u003cp\u003eWoodman, Vernon K. Sondak, Kim A. Margolin, and\u003c\/p\u003e \u003cp\u003eJonathan S. Zager\u003c\/p\u003e \u003cp\u003e107 Other skin cancers 1437\u003c\/p\u003e \u003cp\u003eStacy L. McMurray,William G. Stebbins, Eric A.\u003c\/p\u003e \u003cp\u003eMillican, and Victor A. Neel\u003c\/p\u003e \u003cp\u003e108 Bone tumors 1451\u003c\/p\u003e \u003cp\u003eTimothy A. Damron\u003c\/p\u003e \u003cp\u003e109 Soft tissue sarcomas 1477\u003c\/p\u003e \u003cp\u003eKatherine A.Thornton, Elizabeth H. Baldini, Robert G.\u003c\/p\u003e \u003cp\u003eMaki, Brian O’Sullivan, Yan Leyfman, and Chandrajit P. Raut\u003c\/p\u003e \u003cp\u003e110 Myelodysplastic syndromes 1501\u003c\/p\u003e \u003cp\u003eUma M. Borate\u003c\/p\u003e \u003cp\u003e111 Acute myeloid leukemia in adults: mast cell\u003c\/p\u003e \u003cp\u003eleukemia and other mast cell neoplasms 1517\u003c\/p\u003e \u003cp\u003eRichardM. Stone, Charles A. Schiffer, and Daniel J. DeAngelo\u003c\/p\u003e \u003cp\u003e112 Chronic myeloid leukemia 1537\u003c\/p\u003e \u003cp\u003eJorge Cortes, Richard T. Silver, and Hagop Kantarjian\u003c\/p\u003e \u003cp\u003e113 Acute lymphoblastic leukemia 1547\u003c\/p\u003e \u003cp\u003eElias Jabbour, Nitin Jain, Hagop Kantarjian, and Susan\u003c\/p\u003e \u003cp\u003eO’Brien\u003c\/p\u003e \u003cp\u003e114 Chronic lymphocytic leukemia 1559\u003c\/p\u003e \u003cp\u003eJacqueline C. Barrientos, Kanti R. Rai, and Joanna M. Rhodes\u003c\/p\u003e \u003cp\u003e115 Hodgkin lymphoma 1569\u003c\/p\u003e \u003cp\u003eDavid J. Straus and Anita Kumar\u003c\/p\u003e \u003cp\u003e116 Clonal hematopoiesis in cancer 1579\u003c\/p\u003e \u003cp\u003ePhilipp J. Rauch and David P. Steensma\u003c\/p\u003e \u003cp\u003e117 Non-Hodgkin’s lymphoma 1587\u003c\/p\u003e \u003cp\u003eArnold S. Freedman and Ann S. LaCasce\u003c\/p\u003e \u003cp\u003e118 Mycosis fungoides and Sézary syndrome 1603\u003c\/p\u003e \u003cp\u003eWalter Hanel, Catherine Chung, and John C. Reneau\u003c\/p\u003e \u003cp\u003e119 Plasma cell disorders 1611\u003c\/p\u003e \u003cp\u003eAndrew J. Yee, Teru Hideshima, Noopur Raje, and\u003c\/p\u003e \u003cp\u003eKenneth C. Anderson\u003c\/p\u003e \u003cp\u003e120 Myeloproliferative disorders 1633\u003c\/p\u003e \u003cp\u003eJeanne Palmer and Ruben Mesa\u003c\/p\u003e \u003cp\u003ePart 12: MANAGEMENT OF CANCER\u003c\/p\u003e \u003cp\u003eCOMPLICATIONS\u003c\/p\u003e \u003cp\u003e121 Neoplasms of unknown primary site 1647\u003c\/p\u003e \u003cp\u003eJohn D. Hainsworth and Frank A. Greco\u003c\/p\u003e \u003cp\u003e122 Cancer cachexia 1659\u003c\/p\u003e \u003cp\u003eAssaad A. Eid, Rachel Njeim, Fadlo R. Khuri, and\u003c\/p\u003e \u003cp\u003eDavid K.Thomas\u003c\/p\u003e \u003cp\u003e123 Antiemetic therapy 1673\u003c\/p\u003e \u003cp\u003eMichael J. Berger andDavid S. Ettinger\u003c\/p\u003e \u003cp\u003e124 Neurologic complications of cancer 1683\u003c\/p\u003e \u003cp\u003eLuis Nicolas Gonzalez Castro, Tracy T. Batchelor, and\u003c\/p\u003e \u003cp\u003eLisa M. DeAngelis\u003c\/p\u003e \u003cp\u003e125 Dermatologic complications of cancer\u003c\/p\u003e \u003cp\u003echemotherapy 1701\u003c\/p\u003e \u003cp\u003eAnisha B. Patel, Padmavathi V. Karri, and Madeleine Duvic\u003c\/p\u003e \u003cp\u003e126 Skeletal complications 1715\u003c\/p\u003e \u003cp\u003eMichael A. Via, Ilya Iofin, Jerry Liu, and Jeffrey I. Mechanick\u003c\/p\u003e \u003cp\u003e127 Hematologic complications and blood bank\u003c\/p\u003e \u003cp\u003esupport 1729\u003c\/p\u003e \u003cp\u003eRoger Belizaire and Kenneth C. Anderson\u003c\/p\u003e \u003cp\u003e128 Coagulation complications of cancer patients 1739\u003c\/p\u003e \u003cp\u003eTzu-FeiWang and Kristin Sanfilippo\u003c\/p\u003e \u003cp\u003e129 Urologic complications related to cancer and its\u003c\/p\u003e \u003cp\u003etreatment 1747\u003c\/p\u003e \u003cp\u003eOmar Alhalabi, Ala Abudayyeh, and Nizar M. Tannir\u003c\/p\u003e \u003cp\u003e130 Cardiac complications 1757\u003c\/p\u003e \u003cp\u003eMichael S. Ewer, Steven M. Ewer, andThomas M. Suter\u003c\/p\u003e \u003cp\u003e131 Respiratory complications 1779\u003c\/p\u003e \u003cp\u003eVickie R. Shannon, George A. Eapen, Carlos A. Jimenez,\u003c\/p\u003e \u003cp\u003eHoriana B. Grosu, Rodolfo C. Morice, Lara Bashoura,\u003c\/p\u003e \u003cp\u003eAjay Sheshadre, Scott E. Evans, Roberto Adachi,\u003c\/p\u003e \u003cp\u003eMichael Kroll, Saadia A. Faiz, Diwakar\u003c\/p\u003e \u003cp\u003eD. Balachandran, Selvaraj E. Pravinkumar,\u003c\/p\u003e \u003cp\u003eand Burton F. Dickey\u003c\/p\u003e \u003cp\u003e132 Gastrointestinal and hepatic complications in\u003c\/p\u003e \u003cp\u003ecancer patients 1811\u003c\/p\u003e \u003cp\u003eRobert S. Bresalier, Emmanuel S. Coronel, and Hao Chi Zhang\u003c\/p\u003e \u003cp\u003e133 Oral complications of cancer and their treatment 1827\u003c\/p\u003e \u003cp\u003eStephen T. Sonis, Anna Yuan, and Alessandro Villa\u003c\/p\u003e \u003cp\u003e134 Gonadal complications 1839\u003c\/p\u003e \u003cp\u003eRobertW. Lentz and Catherine E. Klein\u003c\/p\u003e \u003cp\u003e135 Sexual dysfunction 1849\u003c\/p\u003e \u003cp\u003eLeslie R. Schover\u003c\/p\u003e \u003cp\u003e136 Endocrine complications and paraneoplastic\u003c\/p\u003e \u003cp\u003esyndromes 1855\u003c\/p\u003e \u003cp\u003eSai-Ching J. Yeung and Robert F. Gagel\u003c\/p\u003e \u003cp\u003e137 Infections in patients with cancer 1869\u003c\/p\u003e \u003cp\u003eHarrys A. Torres, Dimitrios P. Kontoyiannis, and\u003c\/p\u003e \u003cp\u003eKenneth V.I. Rolston\u003c\/p\u003e \u003cp\u003e138 Oncologic emergencies 1883\u003c\/p\u003e \u003cp\u003eSai-Ching J. Yeung and Carmen P. Escalante\u003c\/p\u003e \u003cp\u003ePart 13: THE FUTURE OF ONCOLOGY\u003c\/p\u003e \u003cp\u003e139 A vision for twenty-first century healthcare 1907\u003c\/p\u003e \u003cp\u003eLeroy Hood, Nathan D. Price, and James T. Yurkovich\u003c\/p\u003e \u003cp\u003eIndex 1915\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e  \u003cp\u003eEdited by \u003c\/p\u003e\u003cp\u003e\u003cb\u003eRobert C. Bast Jr., MD,\u003c\/b\u003e Vice President for Translational Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA \u003c\/p\u003e\u003cp\u003e\u003cb\u003eJohn C. Byrd, MD,\u003c\/b\u003e The Gordon and Helen Hughes Taylor Professor and Chair, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA \u003c\/p\u003e\u003cp\u003e\u003cb\u003eCarlo Croce, MD,\u003c\/b\u003e Distinguished University Professor, The Ohio State University, The John W. Wolfe Chair in Human Cancer Genetics, Professor and Chair, Department of Cancer Biology and Genetics The Wexner Medical Center, The Ohio State University, Columbus, OH, USA \u003c\/p\u003e\u003cp\u003e\u003cb\u003eErnest Hawk, MD, MPH, \u003c\/b\u003eVice President for Cancer Prevention \u0026amp; Head, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA \u003c\/p\u003e\u003cp\u003e\u003cb\u003eFadlo R. Khuri, MD,\u003c\/b\u003e President and Professor of Internal Medicine, Hematology and Medical Oncology, The American University of Beirut, Beirut, Lebanon \u003c\/p\u003e\u003cp\u003e\u003cb\u003eRaphael Pollock, MD, PhD, FACS,\u003c\/b\u003e Director, The Ohio State University Comprehensive Cancer Center, Kathleen Wellenreiter Klotz Chair in Cancer Research, The Ohio State University Wexner Medical Center, Columbus, OH, USA \u003c\/p\u003e\u003cp\u003e\u003cb\u003eApostolia M. Tsimberidou, MD, PhD, \u003c\/b\u003eProfessor, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA \u003c\/p\u003e\u003cp\u003e\u003cb\u003eChristopher Willett, MD, \u003c\/b\u003eProfessor and Chair, Department of Radiation Oncology, Duke University School of Medicine, Boston, Massachusetts, USA \u003c\/p\u003e\u003cp\u003e\u003cb\u003eCheryl Willman, MD, \u003c\/b\u003eExecutive Director, Mayo Clinic Cancer Center Programs: Mayo Rochester\/Midwest, Mayo Arizona, Mayo Florida, London, Abu Dhabi, Director, Mayo Clinic Comprehensive Cancer Center, Professor of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic Cancer Center, Rochester, NY, USA   \u003c\/p\u003e\u003cp\u003e\u003cb\u003eThe latest edition of the gold-standard in cancer science and clinical oncology references\u003c\/b\u003e \u003c\/p\u003e\u003cp\u003eIn the newly revised Tenth Edition of \u003ci\u003eHolland-Frei Cancer Medicine\u003c\/i\u003e, a team of distinguished researchers and practitioners delivers a comprehensive and up-to-date discussion of cancer science and clinical oncology practice. The book contains timely and indispensable information on epidemiology, etiology, cancer biology, immunology, prevention, screening, clinical presentation, pathology, imaging, and therapy. \u003c\/p\u003e\u003cp\u003eGrounded in a fundamental understanding of cancer biology, \u003ci\u003eHolland-Frei Cancer Medicine\u003c\/i\u003e combines scientific principles with clinical practice. It contains hundreds of full-color illustrations and photographs, tables, graphs, and algorithms that complement and enhance the complex topics discussed within the book. This book is an invaluable clinical tool that provides readers with overview boxes, additional references, and other pedagogic features designed to make the content easy to access and comprehend. \u003c\/p\u003e\u003cp\u003eReaders will also find: \u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e A translational and integrated approach throughout the book that combines cancer biology with cancer management\u003c\/li\u003e \u003cli\u003e A strong emphasis on multidisciplinary, research-driven patient care that improves outcomes and allows for the optimal use of all clinically appropriate therapies\u003c\/li\u003e \u003cli\u003e Discussions of the most current personalized cancer care, including molecular diagnostics and therapeutics\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003ePerfect for medical oncologists, radiation oncologists, and internists, \u003ci\u003eHolland-Frei Cancer Medicine, Tenth Edition \u003c\/i\u003ewill also earn a place in the libraries of allied health professionals involved in the treatment of cancer patients.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989367210213,"sku":"NP9781119750680","price":399.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119750680.jpg?v=1761783838","url":"https:\/\/k12savings.com\/es\/products\/holland-frei-cancer-medicine-isbn-9781119750680","provider":"K12savings","version":"1.0","type":"link"}